Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This study evaluates whether preoperative statin therapy improves clinical outcomes in patients referred to coronary artery bypass grafting (CABG) for acute coronary syndrome (ACS).
Methods: A total of 1,151 patients undergoing CABG for ACS were prospectively entered into the North-Rhine-Westphalia surgical myocardial infarction registry and subdivided into two groups according to their preoperative statin status (statin naive vs. statin group). A logistic regression model was employed to analyze the impact of a statin therapy and dose for the endpoints in-hospital mortality and major adverse cardiac events (MACE).
Results: Demographics, pre- and intraoperative data of the statin-naive group ( = 208; 18%) and statin-treated group ( = 943, 82%) did not differ. In-hospital mortality (12.6 vs. 6.3%, = 0.002) and MACE rates (22.1 vs. 9.7%, < 0.001) were significantly higher in statin naive when compared with statin-treated patients with ACS, respectively. Mevalonic acid revealed that both low- and high-dose statin treatment was associated to a reduction in in-hospital mortality and MACE, without a dose-dependent statin effect.
Conclusion: Statin therapy in patients with ACS undergoing CABG reduces in a dose-independent manner in-hospital mortality and MACE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0037-1602257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-Center Health Informatics to Examine the Implementation of Guideline-Directed Medical Therapy in Chronic Kidney Disease.
J Prim Care Community Health
September 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.
View Article and Find Full Text PDFEnhancing Primary Care Capacity for Cardiovascular Disease Management Through the ECHO+ Model: A Multistate Rural Collaboration Among West Virginia, Arkansas, and Oklahoma.
J Prim Care Community Health
September 2025
Office for Research Initiatives and Global Programs, Harvard Medical School, Boston, MA, USA.
Background: Cardiovascular diseases (CVD) are the leading cause of mortality in Arkansas, West Virginia, and Oklahoma, underscoring the need for approaches to build primary care capacity to address CVD in these states.
Methods: The "ECHO+" model integrates a CVD-focused tele-education course with quality improvement (QI) training and coaching to empower rural primary care providers (PCPs) in diagnosing and managing CVD effectively.
Results: 41 clinicians participated in the program.
Poor Performance Status, Diabetes Mellitus, and Statin use are Risk Factors for Decreased Skeletal Muscle Mass During Nab-paclitaxel Plus Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer.
Pancreas
September 2025
Department of Clinical Oncology, Higashiosaka City Medical Center, Higashiosaka, Japan.
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.
Eur Heart J
September 2025
Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Cardiovascular disease remains a major global health challenge, with dyslipidaemia being a key modifiable risk factor. While low density lipoprotein cholesterol (LDL-C) is the primary target for lipid-lowering therapies, recent evidence highlights the importance of triglycerides, apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] for residual cardiovascular risk. Current lipid-lowering therapies target key enzymes and proteins involved in cholesterol and lipid metabolism.
View Article and Find Full Text PDFPharmacogenomic analysis of low-density lipoprotein receptor 3' untranslated region genetic variants influencing rosuvastatin efficacy in Chinese dyslipidemia patients.
Pharmacogenet Genomics
September 2025
Department of Cardiology, Tengzhou Central People's Hospital, Tengzhou, Shandong.
Objectives: Dyslipidemia is a crucial risk factor for atherosclerotic cardiovascular disease. Although rosuvastatin is widely used, treatment response varies significantly due to genetic variation. This study investigated the pharmacogenomic impact of low-density lipoprotein receptor (LDLR) 3' untranslated region (UTR) variants on rosuvastatin efficacy in a Chinese Han adult cohort with dyslipidemia.
View Article and Find Full Text PDF